多发性骨髓瘤靶向治疗研究进展

摘要

随着靶向药物如蛋白酶体抑制剂(PI)、免疫调节剂(IMiD)以及自体造血干细胞移植(ASCT)在临床的应用,患者的预后得到了很大改善.但目前多发性骨髓瘤(MM)仍不可治愈,疾病最终会进展或复发.因此,研发不同作用机制的新药以及改良治疗方案以消除肿瘤克隆,提高缓解深度至关重要.目前,国外新药研发方兴未艾,虽然这些新药大多处于临床试验的不同阶段,试验早期的数据显示,新药使得MM患者获得了更深、更持久的缓解,且药物的安全性和有效性也较为可靠,具有较好的临床应用前景.其中,多种新药联合PI或IMiD的治疗方案有望为MM提供新的治疗选择.文章就近年来MM的靶向新药的研究进展进行综述.%With the wide clinical application of proteasome inhibitors (PI), immunomodulary drugs (IMiD) and autologous stem cell transplantation (ASCT), the prognosis of multiple myeloma (MM) patients has been dramatically improved. However, MM is still an incurable disease, becoming relapse or disease progression finally. Therefore, the development of new drugs with varying mechanisms and the improvement of treatment regimens can help to eradicate the tumor clone and deepen the degree of disease remission. Although most new agents are in different stages of clinical trials, the emerging development of novel agents abroad currently has made MM patients obtain deeper and more enduring remission according to the early experimental data, adding the good safety and efficacy of the new drugs, which could bring the promising clinical application. Varieties of novel drugs combined with PI or IMiD could provide new treatment regimens for MM. This paper reviews the recent progress of the targeted novel drugs of MM.